Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that the positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME), will be presented as a late-breaking abstract at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting, taking place Friday, November 3, 2023 through Monday, November 6, 2023 in San Francisco, California.
Search This Blog
Wednesday, November 1, 2023
Oculis Details Positive Stage 1 Results from Phase 3 Trial for Diabetic Macular Edema
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.